<< Back
Inovio Pharmaceuticals' Novel DNA Vaccine for Clade C HIV Achieves Immune Responses and Protection in Non-Human Primates
Significant T-cell and antibody responses demonstrate the potential of PENNVAX(TM) DNA vaccines delivered using electroporation

BLUE BELL, Pa., Jan 10, 2011 (BUSINESS WIRE) --

Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C viruses in the journal Vaccine. Clade C is the predominant HIV-1 strain infecting people in sub-Saharan Africa, India, and China, and there is a critical need for a vaccine targeted to these areas.

The study, conducted by Inovio scientists and their collaborators, is described in the published paper, entitled "High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation." In this study, the vaccine induced strong antibody and T-cell immune responses in rhesus monkeys. Furthermore, the vaccinated monkeys displayed protective effects against a subsequent challenge with an infectious dose of SHIV virus (chimeric HIV/SIV virus) compared to the placebo control animals. These results further support the proof of concept for Inovio's global DNA vaccine candidates, PENNVAX(TM)-G (vaccine against HIV Clades A, C, and D) and PENNVAX(TM)-GP (vaccine against HIV Clades A, B, and C) in a relevant preclinical model. PENNVAX(TM)-G is currently being tested in a 92-patient global Phase I clinical study (RV-262) conducted by the U.S. Military HIV Vaccine Research Program (MHRP). PENNVAX-GP is being developed using a multi-year $23.5 million NIAID HIV vaccine development contract awarded to Inovio.

Inovio recently announced interim immunogenicity and safety data from its Phase I clinical study of PENNVAX(TM)-B, a DNA vaccine for the prevention of HIV Clade B infection. PENNVAX-B achieved high vaccine-induced response rates and strong magnitude of T-cell immune responses in vaccinated subjects. Similar to reported results from a Phase I clinical study of Inovio's therapeutic DNA vaccine for cervical cancer, the response rates and magnitude of responses achieved in this study were significantly higher than those seen previously with other DNA vaccine trials. Complete immunogenicity data as well as end-of-study safety data from the PENNVAX-B study are expected in 2Q 2011.

Dr. J. Joseph Kim, Inovio's president and CEO, said: "In the past year, we were able to demonstrate best-in-class clinical immunogenicity data from our DNA vaccines for cervical cancer and HIV. We look forward to advancing our cervical cancer candidate into Phase II studies this quarter and completing the preventive HIV study in the next quarter. The data from this study is supportive of the ongoing Phase I clinical program, under the RV-262 protocol, and we are excited about the significant preclinical progress of our PENNVAX-GP global HIV vaccine program. These results further support the prospect that Inovio's DNA vaccine and delivery platform could play an important role in developing new vaccines and therapies for major diseases like HIV."

Inovio's PENNVAX-G vaccine is currently being tested in 12 HIV-uninfected participants in the U.S. Once the vaccine has been assessed as safe and acceptable, the study will expand to three additional global MHRP sites: Kericho, Kenya; Kampala, Uganda; Mbeya, Tanzania. Healthy, HIV-uninfected participants will be enrolled at each of these sites for a total of 80 international participants.

IND-enabling preclinical work for PENNVAX-GP will be conducted in 2011 and the Phase I study is planned to be initiated in 2012.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon(TM) vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV-caused cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, HIV Vaccines Trial Network, National Microbiology Laboratory of the Public Health Agency of Canada, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

SOURCE: Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals
Bernie Hertel, 858-410-3101 (Investors)
bhertel@inovio.com
or
Richardson & Associates
Jeff Richardson, 805-491-8313 (Media)
jeff@richardsonglobalpr.com
Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\10\105128\Disclaimers.xml'.